Bonnie Hall

Dr. Bonnie Hall

University of Pittsburgh School of Medicine

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in Expert Review of Neurotherapeutics
Verified
Journal Article
Closed access
PGPaola Grandi
Paola Grandi
PPPierpaolo Peruzzi
Pierpaolo Peruzzi
BHBonnie Hall
Bonnie Hall
JCJustus Cohen
Justus Cohen
ECE Antonio Chiocca
E Antonio Chiocca
JGJoseph Charles Glorioso
Joseph Charles Glorioso
(2009). Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Review of Neurotherapeutics: Vol. 9, No. 4, pp. 505-517.

Verified
Journal Article
Open access
PDF file
BHBonnie Hall
Bonnie Hall
DLDaniela Leronni
Daniela Leronni
YMYoshitaka Miyagawa
Yoshitaka Miyagawa
WGWilliam F. Goins
William F. Goins
JGJoseph Charles Glorioso
Joseph Charles Glorioso
JCJustus Cohen
Justus Cohen
Oncolytic herpes simplex viruses (oHSV) are under development for the treatment of a variety of human cancers, including breast cancer, a leading cause of cancer mortality among women worldwide. Here we report the design of a fully retargeted oHSV for preferential infection of breast cancer cells through virus recognition of GFRα1, the cellular receptor for glial cell-derived neurotrophic factor (GDNF). GFRα1 displays a limited expression profile in normal adult tissue, but is upregulated in a subset of breast cancers. We generated a recombinant HSV expressing a completely retargeted glycoprotein D (gD), the viral attachment/entry protein, that incorporates pre-pro-GDNF in place of the signal peptide and HVEM binding domain of gD and contains a deletion of amino acid 38 to eliminate nectin-1 binding. We show that GFRα1 is necessary and sufficient for infection by the purified recombinant virus. Moreover, this virus enters and spreads in GFRα1-positive breast cancer cells in vitro and caused tumor regression upon intratumoral injection in vivo. Given the heterogeneity observed between and within individual breast cancers at the molecular level, these results expand our ability to deliver oHSV to specific tumors and suggest opportunities to enhance drug or viral treatments aimed at other receptors.